The association of clinical outcome to front-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma (mRCC) patients (Pts)
| Autor: | G. A. Bjarnason, Mhd Yaser Al-Marrawi, Lauren C. Harshman, Lori Wood, Scott North, D. Y. Heng, Toni K. Choueiri, U. N. Vaishampayan, Sun Young Rha, F. Donskov, Christian K. Kollmannsberger, Neeraj Agarwal, Mary J. MacKenzie, Jennifer J. Knox, Min-Han Tan, Brian I. Rini |
|---|---|
| Rok vydání: | 2011 |
| Předmět: | |
| Zdroj: | Journal of Clinical Oncology. 29:4555-4555 |
| ISSN: | 1527-7755 0732-183X |
| DOI: | 10.1200/jco.2011.29.15_suppl.4555 |
| Popis: | 4555 Background: In mRCC pts who fail first-line VEGF-targeted therapy, there are no available randomized data comparing active drugs. Currently, many clinicians choose a second-line VEGF-targeted therapy based on the type of response to first-line VEGF therapy, although no data exists to support this practice. Methods: Pts treated with targeted therapy in the International mRCC Database Consortium were examined to identify pts who received a second-line VEGF-targeted therapy after failure of a different first-line VEGF-targeted therapy. Response rates and progression-free survival (PFS) were compared in the first- and second-line settings. Results: Of 1,602 total database pts, 464 pts received second-line VEGF-targeted therapy (sunitinib 37%, sorafenib 51%, axitinib 2%, bevacizumab 7%, pazopanib 3%) after failure of first-line VEGF-targeted therapy (sunitinib 54%, sorafenib 33%, bevacizumab 13%). The median overall survival from initiation of first-line therapy for pts who received second-line therapy wa... |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|